reports
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 18 December 2025 to 24 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 18 December 2025 to 24 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 49 066 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 18 december 2025 tot 24 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 18 december 2025 tot 24 december 2025, Kepler ...
- Carole Braudeau
- Carole Braudeau
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
Ontex Group NV: 1 director
A director at Ontex Group NV bought 5,000 shares at 4.630EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly ...
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 11 December 2025 to 17 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 11 December 2025 to 17 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 50 000 shares. Th...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 11 december 2025 tot 17 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 11 december 2025 tot 17 december 2025, Kepler...
Bekaert: Transparency Law
Bekaert: Transparency Law Transparency LawDisclosure in accordance with the Law of 2 May 2007 Pursuant to Articles 15 §1 and 18 §1 of the Law of 2 May 2007 on the disclosure of major holdings in issuers whose shares are admitted to trading on a regulated market, NV Bekaert SA (“Bekaert”) publishes the following information: Status as of 15 December 2025 Basic data Total capital: € 159 782 000.00 Total number of securities conferring voting rights: 51 315 868 shares Total number of voting rights (the denominator): 51 315 868 (one voting right per share) Rea...
Bekaert: Transparantiewetgeving
Bekaert: Transparantiewetgeving TransparantiewetgevingOpenbaarmaking conform de Wet van 2 mei 2007 Conform artikelen 15 §1 en 18 §1 van de Wet van 2 mei 2007 op de openbaarmaking van belangrijke deelnemingen in emittenten waarvan aandelen zijn toegelaten tot de verhandeling op een gereglementeerde markt maakt NV Bekaert SA (“Bekaert”) volgende informatie bekend: Toestand op 15 december 2025 Basisgegevens Totaal kapitaal: € 159 782 000,00 Totaal aantal stemrechtverlenende effecten: 51 315 868 aandelen Totaal aantal stemrechten (de noemer): 51 315 868 (één st...
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Michiel Declercq
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Wim Hoste
Ontex Model update post profit warning
Ontex issued a severe profit warning which implies the company now expects 4Q25 adjusted EBITDA to land at € 38-43m vs a previous expectation range of € 63-68m, with the downwards revision due to intense competition from A-brands in the baby care segment. We have reduced our adjusted EBITDA forecasts for FY25-27 by between 8-10%, but still expect FY26 EBITDA to grow by c. 12% vs our new FY25 forecast, on a combination of efficiency measures, the full contribution of new contracts and (at some po...
- Jacob Mekhael
argenx Vyvgart phase 3 in TED stopped due to lack of efficacy
argenx announced that the phase 3 (UplighTED) studies evaluating Vyvgart subcutaneous (SC) in adults with moderate to severe thyroid eye disease (TED) will be discontinued following a pre-specified unblinded interim analysis from patients completing 24 weeks of treatment. The decision to stop the trial due to lack of efficacy in TED is disappointing, however, the company notes that its pipeline strategy anticipates attrition. Of the 2026 phase 3 readouts, TED was the only program where argenx le...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyr...
argenx Provides Update on UplighTED Studies of Efgartigimod SC in Thyroid Eye Disease 15 December, 2025, 7:00 AM CET Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the Phase 3 UplighTED studies evaluating efgartigimod subcutaneous (SC) (efgartigimod alfa and hyaluronidase-qvfc) in adults with moderate to severe thyroid eye disease (TED) will be discontinued. The decision is based on the recommendation from an Independent Data Monitoring ...
- Carole Braudeau
- Carole Braudeau
Bekaert - Update on the Share Buyback Program and Liquidity Agreement
Bekaert - Update on the Share Buyback Program and Liquidity Agreement Update on the Share Buyback Program and the Liquidity Agreement Period from 4 December 2025 to 10 December 2025 Share Buyback ProgramOn , Bekaert announced the start of the next tranche of its share buyback program, for a total maximum consideration of up to € 25 million. As announced previously, the purpose of the Program is to cancel all shares repurchased. Bekaert announces today that during the period from 4 December 2025 to 10 December 2025, Kepler Cheuvreux SA on behalf of Bekaert has bought 50 000 shares. The ...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquid...
Bekaert - Update over het Inkoopprogramma van Eigen Aandelen en Liquiditeitsovereenkomst Update over het Inkoopprogramma van Eigen Aandelen en de Liquiditeitsovereenkomst Periode van 4 december 2025 tot 10 december 2025 Inkoopprogramma van Eigen AandelenOp , kondigde Bekaert de start aan van de volgende tranche van haar inkoopprogramma, voor een totaalbedrag van maximaal € 25 miljoen. Zoals eerder aangekondigd heeft het inkoopprogramma tot doel alle ingekochte aandelen te vernietigen. Bekaert kondigt vandaag aan dat gedurende de periode van 4 december 2025 tot 10 december 2025, Kepler C...
- Felix Fischer
- Haidje Rustau
- Jayanth Kandalam
- Peter Low
- Si Yong Ng
- Tanvi Arora
- Carole Braudeau
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.